BridgeBio Pharma, Inc.
http://bridgebio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BridgeBio Pharma, Inc.
BridgeBio Spins Out Cancer Arm With $200m Fundraise
BridgeBio will narrow its focus to rare diseases and the November action date for acoramidis, while subsidiary TheRas will become BridgeBio Oncology Therapeutics, focused on KRAS-targeted drugs.
Bayer’s New Pharma Leader To Spearhead Growth From US
The troubled conglomerate is accelerating its moves to streamline its business, with the creation of a more customer- and US-focused pharma division.
Finance Watch: The Biggest Biopharma IPO Of 2024 May Not Happen In The US
Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.
AstraZeneca Spends $800m On Amolyt And Awaits A Readout
The Phase III trial of hypoparathyroidism asset eneboparatide will have to hit if AstraZeneca is going to carve out market share from Ascendis.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Adrenas Therapeutics
- Aspa Therapeutics
- Audition Therapeutics
- Calcilytix Therapeutics
- CoA Therapeutics
- Fortify Therapeutics
- Origin Biosciences
- Phoenix Tissue Repair, Inc.
- QED Therapeutics
- Retinagenix LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice